Gwenaelle Geleoc

Dr. Gwenaelle Geleoc

Otolaryngology, Boston Children's Hospital, Boston, Massachusetts, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2017 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
BPBifeng Pan
Bifeng Pan
CACharles Askew
Charles Askew
AGAlice Galvin
Alice Galvin
SHSelena Heman-Ackah
Selena Heman-Ackah
YAYukako Asai
Yukako Asai
GGGwenaelle Geleoc
Gwenaelle Geleoc
Gene therapy in the inner ear achieves unprecedented recovery of hearing and balance behavior in Usher syndrome mice. Because there are currently no biological treatments for hearing loss, we sought to advance gene therapy approaches to treat genetic deafness. We focused on Usher syndrome, a devastating genetic disorder that causes blindness, balance disorders and profound deafness, and studied a knock-in mouse model, Ush1c c.216G>A, for Usher syndrome type IC (USH1C). As restoration of complex auditory and balance function is likely to require gene delivery systems that target auditory and vestibular sensory cells with high efficiency, we delivered wild-type Ush1c into the inner ear of Ush1c c.216G>A mice using a synthetic adeno-associated viral vector, Anc80L65, shown to transduce 80–90% of sensory hair cells. We demonstrate recovery of gene and protein expression, restoration of sensory cell function, rescue of complex auditory function and recovery of hearing and balance behavior to near wild-type levels. The data represent unprecedented recovery of inner ear function and suggest that biological therapies to treat deafness may be suitable for translation to humans with genetic inner ear disorders.

9 May 2014 in Science
Verified
Journal Article
Closed access
PDF file
GGGwenaelle Geleoc
Gwenaelle Geleoc
JHJeffrey R Holt
Jeffrey R Holt
Hearing Aid: Many millions of people across the globe are subject to hearing loss. Géléoc and Holt ( 10.1126/science.1241062 ) review recent developments in potential therapeutic strategies to restore inner-ear function in patients with acquired or genetic forms of deafness. While challenges remain, fundamental research in molecular, gene, and stem-cell therapies has enabled progress toward developing alternatives to conventional, sound amplification–based prostheses.

3 July 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BGBence György
Bence György
CNCarl Nist-Lund
Carl Nist-Lund
BPBifeng Pan
Bifeng Pan
YAYukako Asai
Yukako Asai
KKK. Domenica Karavitaki
K. Domenica Karavitaki
DCDavid P. Corey
David P. Corey

22 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CNCarl A. Nist-Lund
Carl A. Nist-Lund
BPBifeng Pan
Bifeng Pan
APAmy Patterson
Amy Patterson
YAYukako Asai
Yukako Asai
TCTianwen Chen
Tianwen Chen
JHJeffrey R Holt
Jeffrey R Holt
Fifty percent of inner ear disorders are caused by genetic mutations. To develop treatments for genetic inner ear disorders, we designed gene replacement therapies using synthetic adeno-associated viral vectors to deliver the coding sequence for Transmembrane Channel-Like (Tmc) 1 or 2 into sensory hair cells of mice with hearing and balance deficits due to mutations in Tmc1 and closely related Tmc2. Here we report restoration of function in inner and outer hair cells, enhanced hair cell survival, restoration of cochlear and vestibular function, restoration of neural responses in auditory cortex and recovery of behavioral responses to auditory and vestibular stimulation. Secondarily, we find that inner ear Tmc gene therapy restores breeding efficiency, litter survival and normal growth rates in mouse models of genetic inner ear dysfunction. Although challenges remain, the data suggest that Tmc gene therapy may be well suited for further development and perhaps translation to clinical application.

1 September 2020 in Hearing Research
Verified
Journal Article
Closed access
GGGwenaelle Geleoc
Gwenaelle Geleoc
Aziz El-AmraouiAziz El-Amraoui
Aziz El-Amraoui

1 December 2020 in Molecular Therapy
Verified
Journal Article
Open access
Jennifer J. LentzJennifer J. Lentz
Jennifer J. Lentz
BPBifeng Pan
Bifeng Pan
APAbhilash Ponnath
Abhilash Ponnath
CTChristopher M. Tran
Christopher M. Tran
CNCarl Nist-Lund
Carl Nist-Lund
GGGwenaelle Geleoc
Gwenaelle Geleoc
Usher syndrome is a syndromic form of hereditary hearing impairment that includes sensorineural hearing loss and delayed-onset retinitis pigmentosa (RP). Type 1 Usher syndrome (USH1) is characterized by congenital profound sensorineural hearing impairment and vestibular areflexia, with adolescent-onset RP. Systemic treatment with antisense oligonucleotides (ASOs) targeting the human USH1C c.216G>A splicing mutation in a knockin mouse model of USH1 restores hearing and balance. Herein, we explore the effect of delivering ASOs locally to the ear to treat hearing and vestibular dysfunction associated with Usher syndrome. Three localized delivery strategies were investigated in USH1C mice: inner ear injection, trans-tympanic membrane injection, and topical tympanic membrane application. We demonstrate, for the first time, that ASOs delivered directly to the ear correct Ush1c expression in inner ear tissue, improve cochlear hair cell transduction currents, restore vestibular afferent irregularity, spontaneous firing rate, and sensitivity to head rotation, and successfully recover hearing thresholds and balance behaviors in USH1C mice. We conclude that local delivery of ASOs to the middle and inner ear reach hair cells and can rescue both hearing and balance. These results also demonstrate the therapeutic potential of ASOs to treat hearing and balance deficits associated with Usher syndrome and other ear diseases.